Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Comment by porksnifferon Feb 04, 2019 11:27am
102 Views
Post# 29314741

RE:RE:Apotex being sold Piecemeal

RE:RE:Apotex being sold Piecemeal
TheRock077 wrote: Lots of mega options here.

Other than Cipher, I still think that Paladin Canada will become available this year.

Endo has less than $1.5 billion in cash and $8 billion in debt.
It seems inconceivable that the opioid litigation against Endo will result in class action awards of less than $5 billion.

At what point Endo declares chapter 11 is anyone's guess , but once the award becomes obvious would be the latest timing.



Endo will NOT be declaring bankruptcy, if this were issue the stock would be @ $2.00 not $10.
I'm still waiting for Valeant to declare bankruptcy as per several morons on this forum.
Furthermore insurance will cover a good portion of the litigation and Purdue will be bearing the majority of the liability and not Endo. Palladin will be up for sale but not for pennies on the dollar that you believe or try and convince everyone here to believe. You were the biggest critic of this CEO and now you have your pom poms out. You need to stop your mindless pumping and give your head a shake. Your credibility is already at zero anyway. smh
Bullboard Posts